PhotoCure ASAFRA:PHS +0.77%74 ROC (Joel Greenblatt) % is 498.57% as of Mar. 2026. GuruFocus rates FRA:PHS with a GF Score™ of 74/100 and a GF Value™ of €6.35 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 975 Drug Manufacturers companies, PhotoCure ASA ranks better than 97.64% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. PhotoCure ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 498.57%.
The historical rank and industry rank for PhotoCure ASA's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:PHS'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1395.59 Med: -65.35 Max: 522.6
Current: 234.81
During the past 13 years, PhotoCure ASA's highest ROC (Joel Greenblatt) % was 522.60%. The lowest was -1395.59%. And the median was -65.35%.
FRA:PHS's ROC (Joel Greenblatt) % is ranked better than 97.64% of 975
companies
in the Drug Manufacturers industry
Industry Median: 11.44
vs FRA:PHS: 234.81
PhotoCure ASA's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
PhotoCure ASA ROC (Joel Greenblatt) % Related Terms
PhotoCure ASA ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for PhotoCure ASA's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PHS vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhotoCure ASA ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where PhotoCure ASA's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 498.57% mean?
PhotoCure ASA (FRA:PHS) has a ROC (Joel Greenblatt) % of 498.57% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on PhotoCure ASA and its competitors. According to the industry distribution chart, PhotoCure ASA ranks #23 out of 975 companies in the Drug Manufacturers industry, placing it in the top 2.4%.
Is PhotoCure ASA's ROC (Joel Greenblatt) % too high?
PhotoCure ASA's current ROC (Joel Greenblatt) % is 498.57%. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.44. PhotoCure ASA's value of 498.57% is 4258.1% above this industry median. Based on the distribution chart, PhotoCure ASA ranks #23 out of 975 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PhotoCure ASA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PhotoCure ASA ranks #23 out of 975 companies for ROC (Joel Greenblatt) %. This places PhotoCure ASA in the top 2% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.44. PhotoCure ASA's value of 498.57% is 4258.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.44, based on 975 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PhotoCure ASA's current ROC (Joel Greenblatt) % of 498.57% is 4258.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on PhotoCure ASA and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhotoCure ASA's current ROC (Joel Greenblatt) % is 498.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (FRA:PHS) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.35, compared to a current price of €5.23 — trading 17.6% below its estimated fair value. The current ROC (Joel Greenblatt) % is 498.57% and 4258.1% above the Drug Manufacturers industry median of 11.44. PhotoCure ASA's overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For PhotoCure ASA (FRA:PHS), the current ROC (Joel Greenblatt) % is 498.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?
Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued.
The current stock price of €5.23 is trading 17.6% below its estimated GF Value™ of €6.35.
GuruFocus considers PhotoCure ASA to be Modestly Undervalued.
Key valuation signals for FRA:PHS:
ROC (Joel Greenblatt) %: 498.57%
GF Value™: €6.35 vs. price of €5.23 (17.6% below fair value)
Industry Position: 4258.1% above the Drug Manufacturers median (#23 of 975)
No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
74GF Score
Get the complete analysis for FRA:PHS
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHS has been successfully added to your 
